70 related articles for article (PubMed ID: 10466439)
1. The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1999; 46(2):132-9. PubMed ID: 10466439
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Srp Arh Celok Lek; 1998; 126(11-12):506-11. PubMed ID: 9921027
[TBL] [Abstract][Full Text] [Related]
3. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
4. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
8. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
Ferraresi V; Giampaolo MA; Gabriele A; Mansueto G; Buccilli A; Giannarelli D; Ciccarese M; Gamucci T
J Exp Clin Cancer Res; 2005 Jun; 24(2):187-96. PubMed ID: 16110750
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
11. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
15. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit.
Popov I; Lavrnić S; Jelić S; Jezdić S; Jasović A
Neoplasma; 2002; 49(1):43-8. PubMed ID: 12044059
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
Mambrini A; Bassi C; Pacetti P; Torri T; Iacono C; Ballardini M; Orlandi M; Guadagni S; Fiorentini G; Cantore M
Pancreas; 2008 Jan; 36(1):56-60. PubMed ID: 18192882
[TBL] [Abstract][Full Text] [Related]
17. Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: a prospective randomized study.
Lygidakis NJ; Stringaris K; Kokinis K; Lyberopoulos K; Raptis S
Hepatogastroenterology; 1996; 43(7):212-20. PubMed ID: 8682466
[TBL] [Abstract][Full Text] [Related]
18. First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer.
Garcia-Giralt E; Omodei Zorini C; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
Clin Ter; 1997 Sep; 148(9):393-401. PubMed ID: 9374077
[No Abstract] [Full Text] [Related]
19. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
Assersohn L; Norman A; Cunningham D; Benepal T; Ross PJ; Oates J
Br J Cancer; 1999 Apr; 79(11-12):1800-5. PubMed ID: 10206296
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of advanced colorectal cancer].
Schalhorn A
Fortschr Med; 1991 Mar; 109(8):183-6. PubMed ID: 2055582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
